Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
198.70M | 238.73M | 57.62M | 11.53M | 6.82M | Gross Profit |
180.47M | 35.39M | 41.04M | -684.00K | 2.45M | EBIT |
-217.92M | -310.43M | -166.22M | -180.40M | -224.25M | EBITDA |
-181.97M | -282.03M | -149.34M | -167.59M | -213.07M | Net Income Common Stockholders |
-266.22M | -388.17M | -172.23M | -191.01M | -226.79M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
124.33M | 65.40M | 193.99M | 295.18M | 243.14M | Total Assets |
842.43M | 653.51M | 690.51M | 688.43M | 463.76M | Total Debt |
191.72M | 231.48M | 38.22M | 44.38M | 6.26M | Net Debt |
67.39M | 166.08M | -155.77M | -250.80M | -236.88M | Total Liabilities |
633.89M | 482.17M | 265.63M | 256.69M | 206.06M | Stockholders Equity |
208.54M | 171.34M | 424.89M | 431.74M | 257.71M |
Cash Flow | Free Cash Flow | |||
-185.97M | -423.45M | -254.04M | -296.96M | -242.26M | Operating Cash Flow |
-133.73M | -406.68M | -193.92M | -219.61M | -238.41M | Investing Cash Flow |
-52.25M | -16.77M | -60.13M | -77.35M | -3.85M | Financing Cash Flow |
243.62M | 298.70M | 148.86M | 349.37M | 322.72M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% | |
48 Neutral | kr379.37M | ― | -47.73% | ― | 45.52% | 93.35% | |
44 Neutral | kr267.41M | ― | -18.79% | ― | ― | 21.85% | |
42 Neutral | €367.40M | ― | -24.61% | ― | 47.06% | 33.86% | |
40 Underperform | kr321.97M | ― | ― | 1.72% | 32.54% | ||
36 Underperform | €185.74M | ― | -54.29% | ― | -100.00% | -17.35% | |
32 Underperform | kr375.12M | ― | -205.65% | ― | ― | 24.25% |
Xbrane Biopharma has completed the sale of its biosimilar candidate XB003 and parts of its organization to Alvotech for approximately SEK 275 million. This transaction strengthens Xbrane’s financial position, allowing the company to focus on its remaining programs, particularly Ximluci and Xdivane, and continue its work in biosimilar development to create value for shareholders and patients.
Xbrane Biopharma AB has re-submitted its Biologics License Application to the US FDA for its biosimilar candidate to LUCENTIS® (ranibizumab), aimed at treating conditions such as age-related macular degeneration. The FDA has set a decision date for October 2025, contingent on successful re-inspections of manufacturing sites. This move underscores Xbrane’s commitment to providing cost-effective treatment alternatives and could enhance its position in the biosimilar market.
Xbrane Biopharma AB announced a strategic move to sell its biosimilar candidate XB003 and parts of its organization to Alvotech for approximately SEK 275 million. This transaction is expected to strengthen Xbrane’s financial position by reducing annual fixed costs by around SEK 120 million and allowing the company to focus on its core products, Ximluci® and Xdivane™, which are anticipated to generate significant revenue through royalties and profit sharing. The company also reported strong growth for Ximluci® in Europe and is progressing with regulatory processes in the US, while preparing for a clinical trial for Xdivane™.
Xbrane Biopharma AB’s annual general meeting resulted in several key resolutions, including the adoption of the income statement and balance sheet, the decision not to distribute dividends, and the re-election of board members and auditors. The meeting also established remuneration for directors and committee members and set guidelines for senior executive remuneration, while withdrawing a proposal for issuing shares due to insufficient support.